Views

All Case Studies Views Resources Whitepapers Podcasts On-Demand Webinars
Let’s Recognize the Advances in Lung Cancer this November
Over the past 10 years, tremendous strides have been made in the treatment of lung cancer due in large part due to discoveries of cancer biomarkers such as ALK, EGFR, c-KIT and ROS. In direct correlation, tumors are now classified by their molecular profile resulting in a shift of treatment paradigms and, ultimately better patient outcomes.
View Nov 4, 2019
Part II: Planning the H.A.C. Event
All in, planning the hackathon took five months. In post-event debriefs among the H.A.C. MBC committee, three overarching themes for hosting a successful hackathon emerged: 
View May 22, 2019
Learning to Speak HEOR
As one formulary decision-maker told us: “Recent regulation guidance on FDAMA114 frees up pharma to be more active in sharing HEOR information, and I think that helps.”
View Dec 18, 2018